male reproductive organ cancer: A reproductive organ cancer that is manifested in the male genital system. This includes organs such as the penis and scrotum.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleonly males |
244368 |
2. Check conditionsNone |
244368 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
162 |
4. Check minimum number of eventsNone |
162 |
5. Include endpointsNone |
162 |
6. Filter based on genotype QC (FinnGen only) |
147 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D29
- Name in latin
- Neoplasma benignum scroti
Similar endpoints
↥List of similar endpoints to
Benign neoplasm: Scrotum
based on the number of shared cases.
Similar with more cases:
- Benign neoplasm of male genital organs
- Benign neoplasms
- Neoplasms
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1111 | - | 1111 |
| Only index persons | 936 | - | 936 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | - | 0.03 |
| Only index persons | 0.04 | - | 0.04 |
| Median age at first event (years) | |||
| Whole population | - | - | 43.64 |
| Only index persons | - | - | 40.66 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 147 | - | 147 |
| Unadjusted period prevalence (%) | 0.07 | - | 0.07 |
| Median age at first event (years) | 48.05 | - | 48.05 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 153
- Matched controls
- 1530
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D29.4
ICD-10 Finland
Benign neoplasm: Scrotum
+∞
143.1
114
*
22288
ICD-8 Finland
Benign neoplasm of male genital organs, Loco alio definito
+∞
26.9
25
*
22280
ICD-8 Finland
Benign neoplasm of male genital organs, Scroti
+∞
12.7
12
*
KF8AE
NOMESCO Finland
Ultrasound examination of scrotum
5.4
9.1
19
39
KFD70
NOMESCO Finland
Excision of lesion of skin of scrotum
+∞
8.4
8
*
L72.1
ICD-10 Finland
Trichilemmal cyst
4.4
7.4
20
51
KFW96
NOMESCO Finland
Other operation on scrotum or scrotal organs
+∞
7.3
7
*
D29.2
ICD-10 Finland
Benign neoplasm: Testis
+∞
6.3
6
*
D40.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Testis
13.3
6.2
10
8
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
71
501
1.78
3.03
2.0
2.1
92.27
90.51
pmol/l
0.12
44
284
115
937
1.92
3.02
8.1
9.4
81.02
79.26
u/l
0.11
107
904
72
545
1.61
2.17
6.3
5.9
35.80
35.47
g/l
0.17
65
518
68
508
1.61
2.17
1.8
2.1
1.49
1.49
mmol/l
0.01
59
427
60
437
1.61
2.11
2.3
2.3
79.12
72.81
nmol/l
1.08
54
389
98
807
1.60
2.02
3.3
3.2
14.40
14.76
pmol/l
0.77
92
727
131
1167
1.85
1.93
18.7
16.6
81.53
82.15
ml/min/173m2
0.12
119
1079
107
910
1.58
1.83
5.0
5.3
1.83
2.30
ug/l
0.58
98
821
75
591
1.53
1.81
6.8
8.7
1.21
1.20
mmol/l
0.84
62
521
87
709
1.53
1.79
2.4
2.8
—
—
—
0
0
70
547
1.52
1.74
2.8
2.9
—
—
estimate
—
0
0
42
293
1.60
1.72
2.4
2.0
2.50
2.77
mg/l
0.45
33
262
16
83
2.04
1.72
3.7
2.8
72.45
63.85
ml/min/173m2
0.59
11
39
117
1023
1.61
1.71
4.2
4.1
1.98
2.07
mu/l
0.28
108
932
37
251
1.63
1.70
1.6
1.9
445.80
52232557.92
pmol/l
0.50
30
224
102
876
1.49
1.52
4.0
4.1
11.09
12.05
mm/h
0.27
91
826
68
542
1.46
1.47
6.1
7.4
1.22
1.20
mmol/l
1.31
61
508
17
97
1.85
1.42
5.1
8.9
25.41
24.74
mmol/l
0.27
17
97
29
196
1.59
1.35
1.5
1.7
1036.66
1173.89
nmol/l
0.40
20
153
47
355
1.47
1.32
1.7
1.7
21.13
19.32
nmol/l
0.31
39
299
57
451
1.42
1.25
3.2
4.0
31.90
35.56
u/l
0.59
51
424
128
1177
1.54
1.14
19.3
17.6
31.04
28.10
mg/l
0.28
112
1001
136
1268
1.65
1.14
12.5
12.7
29.58
30.85
u/l
0.34
130
1240
8
40
2.05
1.14
1.5
1.3
0.00
0.00
g/l
—
8
32
100
881
1.39
1.12
3.1
3.9
54.94
61.44
u/l
0.39
93
834
60
488
1.38
1.10
3.1
3.5
0.00
0.02
estimate
0.50
17
122
19
124
1.61
1.02
1.9
2.7
0.28
0.15
e6/l
0.42
19
119
125
1152
1.46
1.02
5.5
5.3
6.04
6.14
mmol/l
0.45
113
1067
9
50
1.85
0.98
1.4
1.4
1.19
1.55
g/l
—
9
42
9
51
1.81
0.96
1.3
1.4
2.90
3.05
g/l
—
9
45
129
1201
1.47
0.94
5.5
5.4
4.26
4.43
mmol/l
1.19
124
1127
10
55
1.88
0.94
1.3
1.3
7.25
7.22
g/l
—
10
49
10
55
1.88
0.94
1.3
1.3
4.50
3.50
g/l
—
10
49
10
55
1.88
0.94
1.3
1.3
4.18
4.17
g/l
—
10
49
37
285
1.39
0.92
2.2
2.6
—
—
—
0
0
55
453
1.33
0.91
3.9
4.4
3.55
9.44
mg/mmol
2.51
37
323
6
30
2.04
0.88
1.3
1.2
—
—
—
0
0
8
44
1.86
0.87
1.5
1.3
0.04
0.00
g/l
—
8
38
78
679
1.30
0.86
10.6
11.4
4.17
4.26
e9/l
0.16
71
596
34
262
1.38
0.85
3.9
3.9
476.64
400.14
ng/l
0.06
28
220
44
354
1.34
0.84
3.3
3.1
1.04
0.53
e6/l
0.21
37
258
8
46
1.78
0.84
1.0
1.3
—
—
—
0
0
12
75
1.65
0.77
5.6
3.5
25.03
23.89
mmol/l
0.74
12
75
138
1313
1.52
0.77
29.6
25.8
138.75
140.87
g/l
0.74
138
1303
124
1159
1.37
0.77
7.8
6.9
39.83
40.13
mmol/mol
0.14
115
1098
44
360
1.31
0.75
2.8
3.4
0.00
0.02
estimate
0.74
19
123
72
629
1.27
0.74
3.1
3.6
0.00
0.00
estimate
-0.00
19
137
71
624
1.26
0.68
3.1
3.5
0.00
0.00
estimate
-0.00
20
136
129
1220
1.37
0.67
6.1
6.0
2.50
2.65
mmol/l
0.92
122
1138
72
639
1.24
0.62
3.1
3.5
0.00
0.00
estimate
-0.00
20
122
12
80
1.54
0.62
1.5
1.4
—
—
—
0
0
124
1171
1.31
0.61
4.6
4.5
1.34
1.39
mmol/l
0.34
116
1093
29
234
1.30
0.55
1.3
1.4
0.79
1.05
u/ml
—
8
71
126
1200
1.28
0.52
5.5
5.3
1.26
1.29
mmol/l
0.43
119
1121
7
45
1.58
0.49
1.1
2.2
—
—
—
0
0
32
267
1.25
0.47
1.7
1.6
0.73
1.69
mg/l
2.86
26
209
61
545
1.20
0.47
2.8
3.1
0.63
0.76
ug/l
0.89
41
356
11
78
1.44
0.44
1.5
1.8
—
—
—
0
0
80
737
1.18
0.43
4.2
4.5
21.46
21.21
%
0.05
40
353
5
33
1.53
0.41
1.0
1.2
—
—
—
0
0
0
15
0.00
0.41
0.0
1.7
—
—
—
0
0
0
15
0.00
0.41
0.0
1.6
—
—
—
0
0
0
15
0.00
0.41
0.0
1.5
—
5.27
—
0
15
0
16
0.00
0.41
0.0
2.2
—
—
—
0
0
0
16
0.00
0.41
0.0
2.2
—
—
—
0
0
0
16
0.00
0.41
0.0
2.2
—
—
—
0
0
25
206
1.26
0.41
5.6
8.5
104.76
104.45
mmol/l
0.15
25
206
28
236
1.23
0.38
1.5
2.2
—
—
—
0
0
12
156
0.75
0.36
1.6
1.5
—
—
—
0
0
6
43
1.41
0.35
1.0
1.0
—
—
—
0
0
47
421
1.17
0.34
3.4
3.4
2980.17
1187.79
ng/l
1.09
36
351
7
55
1.29
0.30
3.6
3.0
—
—
—
0
0
11
86
1.30
0.27
1.6
1.9
—
—
—
0
0
15
124
1.23
0.25
6.2
10.0
1.21
1.33
mmol/l
0.24
15
124
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.7
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.8
—
4.17
—
0
6
0
11
0.00
0.21
0.0
1.6
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.5
—
—
—
0
0
0
12
0.00
0.21
0.0
2.4
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.5
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.8
—
—
—
0
0
10
80
1.27
0.21
1.6
1.8
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
12
143
0.83
0.19
4.2
3.2
—
—
—
0
0
32
293
1.12
0.17
3.1
3.6
1.02
1.02
kg/l
0.88
24
189
39
363
1.10
0.16
2.9
3.2
0.00
0.00
estimate
-0.00
16
112
24
222
1.10
0.11
3.7
2.8
0.55
0.72
e6/l
0.24
15
121
5
44
1.14
0.10
1.8
1.3
—
—
—
0
0
5
44
1.14
0.10
1.2
1.7
—
—
—
0
0
5
45
1.11
0.10
1.2
2.8
103.20
202.78
mg/l
—
5
38
5
45
1.11
0.10
1.2
2.8
36.82
77.71
mg/l
—
5
38
14
126
1.12
0.09
3.4
8.3
—
—
—
0
0
15
136
1.11
0.09
5.9
4.1
6.08
5.58
kpa
1.61
15
131
20
186
1.09
0.07
1.5
2.0
—
—
—
0
0
56
544
1.05
0.06
4.3
4.0
60.21
47.26
ng/l
0.16
41
412
16
148
1.09
0.06
6.3
4.9
26.60
28.97
%
—
10
100
10
110
0.90
0.05
1.0
1.4
—
—
—
0
0
20
211
0.94
0.04
4.0
2.9
0.42
0.38
e6/l
0.08
13
112
37
364
1.02
0.00
2.9
3.1
376.97
369.19
umol/l
0.23
31
316
10
104
0.96
0.00
1.7
1.7
—
—
—
0
0
15
146
1.03
0.00
1.3
1.3
6.12
13.22
u/ml
—
6
56
18
176
1.03
0.00
1.6
2.1
—
—
—
0
0
18
175
1.03
0.00
8.1
9.5
12.84
11.28
kpa
0.68
18
170
16
165
0.97
0.00
1.3
1.2
88.78
39.11
iu/ml
—
6
45
12
122
0.98
0.00
1.6
1.9
434.67
377.30
nmol/l
0.47
12
112
12
115
1.05
0.00
4.5
3.3
5.75
4.70
kpa
0.31
12
109
0
8
0.00
0.00
0.0
2.6
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
10.81
—
0
8
0
7
0.00
-0.00
0.0
2.9
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
66.48
—
0
6
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
3.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
109.00
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
17.96
—
0
5
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
7
0.00
-0.00
0.0
3.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
3.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
25.40
—
0
5
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
3.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint CD2_BENIGN_SCROTUM and mortality.
Females
No dataMales
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CD2_BENIGN_SCROTUM | 1.306 [0.98, 1.74] | 0.067 |
| Birth year | 0.985 [0.98, 1.0] | 0.004 |
During the follow-up period (1.1.1998 — 31.12.2019), 84 out of 605 males with CD2_BENIGN_SCROTUM died.
Mortality risk
Mortality risk for people of age
years, who have CD2_BENIGN_SCROTUM.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | 0.253% |
| 5 | No data | 1.561% |
| 10 | No data | 3.61% |
| 15 | No data | 6.871% |
| 20 | No data | 11.442% |
Relationships between endpoints
↥Index endpoint: CD2_BENIGN_SCROTUM – Benign neoplasm: Scrotum
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data